Mizuho analyst Uy Ear reiterated an Outperform rating and $31.00 price target on Sarepta Therapeutics (NASDAQ: SRPT), saying the HARBOR ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments